PLRX
Pliant Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PLRX Profile
Pliant Therapeutics, Inc.
A clinical stage biopharmaceutical company that developing novel therapies for fibrosis and related diseases
260 Littlefield Avenue, South San Francisco, CA 94080
--
Pliant Therapeutics, Inc., was incorporated in June 2015 under the laws of the State of Delaware. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of new therapies for the treatment of fibrosis. Their initial focus was on treating fibrosis by inhibiting integrin-mediated TGF-β activation. Leveraging their deep understanding of fibrosis biology, as well as their expertise in medicinal chemistry and translational medicine, the company has developed a suite of proprietary tools designed to quickly and effectively discover and reduce the risk of product candidates. Their wholly-owned lead drug candidate, PLN-74809, is an oral small molecule dual selective inhibitor of integrin, which the company is developing for the treatment of idiopathic pulmonary fibrosis or IPF, primary sclerosing cholangitis or PSC.
